Several studies have demonstrated the efficacy of SGLT-2 inhibitors against cancers such as prostate and breast cancer (Aber et al., 2025; Karim et al., 2024; Anastasio et al., 2024; Sokołowska et al., 2025). This evidence concerns the gene SLC5A2 and cancer.